<p>马里兰州盖尔曼镇，2026 年 4 月 30 日（GLOBE NEWSWIRE）-- Senseonics Holdings, Inc.（纳斯达克：SENS）是一家专注于开发、制造和商业化长期植入式连续血糖监测（CGM）系统的医疗科技公司，旨在为糖尿病患者提供服务。今天宣布以每股 5.00 美元的价格公开发行 8,000,000 股普通股，并向某些投资者提供预先融资的认购权证，以购买 8,000,000 股普通股，购买价格为每股 4.999 美元，该价格等于普通股的公开发行价格减去每个预先融资认购权证的 0.001 美元行使价格。预计 Senseonics 从此次发行中获得的总收入（在扣除承销折扣和佣金及估计的发行费用之前）将达到 8000 万美元。此外，Senseonics 还授予承销商一个 30 天的选择权，以在公开发行价格下购买最多 2,400,000 股普通股，扣除承销折扣和佣金。此次发行预计将于 2026 年 5 月 4 日完成，前提是满足惯常的交割条件。预先融资的认购权证将不会在任何证券交易所上市。</p>
<p>TD Cowen 和巴克莱银行担任此次发行的联合账簿管理人，瑞穗银行和湖街资本担任账簿管理人。</p>
<p>此次发行是根据一份 “货架” 注册声明（表格 S-3）进行的，包括于 2025 年 8 月 6 日首次向证券交易委员会（“SEC”）提交并于 2025 年 8 月 18 日生效的基础招股说明书（文件编号：333-289306）。与此次发行相关的初步招股说明书补充及附带招股说明书已向 SEC 提交，并可在 SEC 的网站 www.sec.gov 上获取。与此次发行相关的最终招股说明书补充及附带招股说明书将向 SEC 提交，并将在 SEC 的网站 http://www.sec.gov 上免费提供。最终招股说明书补充及附带招股说明书的副本可通过联系 TD Securities (USA) LLC，地址为 Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，或通过电子邮件联系 TDManualrequest@broadridge.com；或联系巴克莱资本公司，地址为 Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，电话 (888) 603-5847，或通过电子邮件联系 barclaysprospectus@broadridge.com。</p>
<p>Senseonics 打算将此次公开发行的净收益用于资助 Eversense 365 的持续推出和管道产品的开发，以及用于营运资金和一般企业用途。</p>
<p>本新闻稿不构成出售这些证券的要约或购买这些证券的邀请，也不应在任何州或其他司法管辖区进行这些证券的出售，除非在该州或其他司法管辖区的证券法下注册或合格之前。</p>
<p><strong>关于 Senseonics</strong></p>
<p>Senseonics Holdings, Inc.（&#34;Senseonics&#34;）是一家医疗科技公司，专注于开发、制造和商业化血糖监测产品，旨在通过差异化的长期植入式血糖管理技术改变全球糖尿病社区的生活。Senseonics 的 CGM 系统 Eversense <strong>®</strong> 365 和 Eversense <strong>®</strong> E3 包括一个完全植入皮肤下的小型传感器，该传感器与佩戴在传感器上方的智能发射器进行通信。血糖数据每 5 分钟自动发送到用户智能手机上的移动应用程序。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1995 年《私人证券诉讼改革法》定义的前瞻性声明，包括但不限于关于 Senseonics 对发行关闭日期的预期以及预计使用发行收益的声明。&#34;预计&#34;、&#34;潜在&#34;、&#34;可能&#34;、&#34;将&#34;等类似表述旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。实际结果或事件可能因各种重要因素而与这些前瞻性声明中披露的计划、意图和预期大相径庭，包括与 Senseonics 或承销商无法满足发行关闭条件相关的风险；与当前经济环境、市场及其他条件相关的不确定性；以及在 Senseonics 于 2026 年 3 月 2 日向 SEC 提交的 2025 年 12 月 31 日止年度的 10-K 年度报告的风险因素部分及 Senseonics 不时向 SEC 提交的其他文件中描述的其他风险和不确定性。这些前瞻性声明中讨论的事件和情况可能不会发生，Senseonics 的实际结果可能与预期或暗示的结果大相径庭且产生不利影响。本新闻稿中包含的任何前瞻性声明仅代表本日期的观点，Senseonics 明确不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>投资者联系：</strong></p>
<p>Jeremy Feffer</p>
<p>LifeSci Advisors</p>
<p>investors@senseonics.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1USTBNQ00zTlRjM056Y3lJekl5TURNNU16VT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1USTBNQ00zTlRjM056Y3lJekl5TURNNU16VT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGUwYTkzYTgtZDlmZS00MzZhLWI4ZTUtYjliYjliZDJiMmU2LTEyMTU0ODgtMjAyNi0wNS0wMS1lbg==/tiny/Senseonics-Holdings-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGUwYTkzYTgtZDlmZS00MzZhLWI4ZTUtYjliYjliZDJiMmU2LTEyMTU0ODgtMjAyNi0wNS0wMS1lbg==/tiny/Senseonics-Holdings-Inc-.png"/></p>

Senseonics控股

<p>Senseonics 控股公司宣布以每股 5.00 美元的价格公开发行 800 万股普通股，融资总额为 8000 万美元，同时为部分投资者提供预先融资的认股权证。此次发行预计将于 2026 年 5 月 4 日完成，所得款项将用于 Eversense 365 的推出、产品开发和一般企业用途。承销商包括 TD Cowen 和巴克莱，并提供额外 240 万股的 30 天选择权。此次发行是在美国证券交易委员会的货架注册声明下进行的</p>

<p>GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 8,000,000 shares of common stock at a price to the public of $5.00 per share, and in lieu of common stock, to certain investors, pre-funded warrants to purchase 8,000,000 shares of common stock at a purchase price of $4.999 per pre-funded warrant share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds to Senseonics from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $80 million. In addition, Senseonics granted the underwriters a 30-day option to purchase up to an additional 2,400,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 4, 2026, subject to satisfaction of customary closing conditions. The pre-funded warrants will not be listed on any securities exchange.</p>
<div class="lb-trans"><p>马里兰州盖尔曼镇，2026 年 4 月 30 日（GLOBE NEWSWIRE）-- Senseonics Holdings, Inc.（纳斯达克：SENS）是一家专注于开发、制造和商业化长期植入式连续血糖监测（CGM）系统的医疗科技公司，旨在为糖尿病患者提供服务。今天宣布以每股 5.00 美元的价格公开发行 8,000,000 股普通股，并向某些投资者提供预先融资的认购权证，以购买 8,000,000 股普通股，购买价格为每股 4.999 美元，该价格等于普通股的公开发行价格减去每个预先融资认购权证的 0.001 美元行使价格。预计 Senseonics 从此次发行中获得的总收入（在扣除承销折扣和佣金及估计的发行费用之前）将达到 8000 万美元。此外，Senseonics 还授予承销商一个 30 天的选择权，以在公开发行价格下购买最多 2,400,000 股普通股，扣除承销折扣和佣金。此次发行预计将于 2026 年 5 月 4 日完成，前提是满足惯常的交割条件。预先融资的认购权证将不会在任何证券交易所上市。</p>
</div><p>TD Cowen and Barclays are acting as joint book-running managers and Mizuho and Lake Street are acting as bookrunners for the proposed offering.</p>
<div class="lb-trans"><p>TD Cowen 和巴克莱银行担任此次发行的联合账簿管理人，瑞穗银行和湖街资本担任账簿管理人。</p>
</div><p>The proposed offering is being made pursuant to a “shelf” registration statement on Form S-3, including a base prospectus (File No. 333-289306) that was originally filed with the Securities and Exchange Commission (the “SEC”) on August 6, 2025 and became effective on August 18, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, by contacting TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com.</p>
<div class="lb-trans"><p>此次发行是根据一份 “货架” 注册声明（表格 S-3）进行的，包括于 2025 年 8 月 6 日首次向证券交易委员会（“SEC”）提交并于 2025 年 8 月 18 日生效的基础招股说明书（文件编号：333-289306）。与此次发行相关的初步招股说明书补充及附带招股说明书已向 SEC 提交，并可在 SEC 的网站 www.sec.gov 上获取。与此次发行相关的最终招股说明书补充及附带招股说明书将向 SEC 提交，并将在 SEC 的网站 http://www.sec.gov 上免费提供。最终招股说明书补充及附带招股说明书的副本可通过联系 TD Securities (USA) LLC，地址为 Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，或通过电子邮件联系 TDManualrequest@broadridge.com；或联系巴克莱资本公司，地址为 Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，电话 (888) 603-5847，或通过电子邮件联系 barclaysprospectus@broadridge.com。</p>
</div><p>Senseonics intends to use the net proceeds from the public offering to fund the ongoing launch of Eversense 365 and continued development of pipeline products, as well as for working capital and general corporate purposes.</p>
<div class="lb-trans"><p>Senseonics 打算将此次公开发行的净收益用于资助 Eversense 365 的持续推出和管道产品的开发，以及用于营运资金和一般企业用途。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售这些证券的要约或购买这些证券的邀请，也不应在任何州或其他司法管辖区进行这些证券的出售，除非在该州或其他司法管辖区的证券法下注册或合格之前。</p>
</div><p><strong>About Senseonics</strong></p>
<div class="lb-trans"><p><strong>关于 Senseonics</strong></p>
</div><p>Senseonics Holdings, Inc. (&#34;Senseonics&#34;) is a medical technology company focused on the development, manufacturing and commercialization of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense <strong>®</strong> 365 and Eversense <strong>®</strong> E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.</p>
<div class="lb-trans"><p>Senseonics Holdings, Inc.（&#34;Senseonics&#34;）是一家医疗科技公司，专注于开发、制造和商业化血糖监测产品，旨在通过差异化的长期植入式血糖管理技术改变全球糖尿病社区的生活。Senseonics 的 CGM 系统 Eversense <strong>®</strong> 365 和 Eversense <strong>®</strong> E3 包括一个完全植入皮肤下的小型传感器，该传感器与佩戴在传感器上方的智能发射器进行通信。血糖数据每 5 分钟自动发送到用户智能手机上的移动应用程序。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding, among other things, Senseonics’ expectations about the closing date of the offering and the anticipated use of proceeds from the offering. The words “expects,” “potential,” “may,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including risks relating to Senseonics’ inability, or the inability of underwriters, to satisfy the conditions to closing for the offering; uncertainties relating to the current economic environment, market and other conditions; and other risks and uncertainties that are described in the Risk Factors section of Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 2, 2026, and other filings Senseonics makes with the SEC from time to time. The events and circumstances discussed in such forward-looking statements may not occur, and Senseonics’ actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements contained in this press release speak only as of the date hereof, and Senseonics expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1995 年《私人证券诉讼改革法》定义的前瞻性声明，包括但不限于关于 Senseonics 对发行关闭日期的预期以及预计使用发行收益的声明。&#34;预计&#34;、&#34;潜在&#34;、&#34;可能&#34;、&#34;将&#34;等类似表述旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。实际结果或事件可能因各种重要因素而与这些前瞻性声明中披露的计划、意图和预期大相径庭，包括与 Senseonics 或承销商无法满足发行关闭条件相关的风险；与当前经济环境、市场及其他条件相关的不确定性；以及在 Senseonics 于 2026 年 3 月 2 日向 SEC 提交的 2025 年 12 月 31 日止年度的 10-K 年度报告的风险因素部分及 Senseonics 不时向 SEC 提交的其他文件中描述的其他风险和不确定性。这些前瞻性声明中讨论的事件和情况可能不会发生，Senseonics 的实际结果可能与预期或暗示的结果大相径庭且产生不利影响。本新闻稿中包含的任何前瞻性声明仅代表本日期的观点，Senseonics 明确不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>INVESTOR CONTACT:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>Jeremy Feffer</p>
<div class="lb-trans"><p>Jeremy Feffer</p>
</div><p>LifeSci Advisors</p>
<div class="lb-trans"><p>LifeSci Advisors</p>
</div><p>investors@senseonics.com</p>
<div class="lb-trans"><p>investors@senseonics.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1USTBNQ00zTlRjM056Y3lJekl5TURNNU16VT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcxMTI0MCM3NTc3NzcyIzIyMDM5MzU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGUwYTkzYTgtZDlmZS00MzZhLWI4ZTUtYjliYjliZDJiMmU2LTEyMTU0ODgtMjAyNi0wNS0wMS1lbg==/tiny/Senseonics-Holdings-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NGUwYTkzYTgtZDlmZS00MzZhLWI4ZTUtYjliYjliZDJiMmU2LTEyMTU0ODgtMjAyNi0wNS0wMS1lbg==/tiny/Senseonics-Holdings-Inc-.png"/></p>

Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants | SENS Stock News

StockTitan

Senseonics 宣布 8000 万美元普通股和预先资助认股权证的公开发行定价 | SENS 股票新闻